Recital 29, Regulation (EU) 2026/2348

In force

The application for the renewal of the approval of the active substance fenoxaprop-P was submitted on 15 December 2015 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 3 February 2016 that it had assessed the admissibility of the application pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority. On 16 March 2018, the rapporteur Member State submitted the draft renewal assessment report to the Authority, which conducted a public consultation on it between 22 August and 21 November 2022. On 7 December 2018, the Authority requested additional information for the purposes of the renewal assessment pursuant to Article 13(3) of Implementing Regulation (EU) No 844/2012 and the applicant submitted that information on 7 January 2019 within the deadline given. On 12 July 2019, the Authority requested additional information for the purposes of assessment of the approval criteria concerning endocrine disrupting properties set out in points 3.6.5 and 3.8.2 of Annex II to Regulation (EC) No 1107/2009, as amended by Regulation (EU) 2018/605, pursuant to Article 13(3a) of Implementing Regulation (EU) No 844/2012 and the applicant submitted that information on 11 January 2022 within the deadline given. On 30 September 2024, the Authority adopted its conclusion and communicated it to the applicant, the Member States and the Commission. The Commission initiated preliminary discussions on the renewal of the approval of the active substance fenoxaprop-P in the Standing Committee on 4 December 2024. The draft renewal report were first discussed in the Standing Committee on 24 September 2026. As additional time is necessary for the Standing Committee to deliver its opinion and for the Commission to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 9 months, until 31 August 2027.